Indeed, clinical data shows that the normalization of blood glucose in diabetic patients does not reduce cardiovascular death41, and thiazolidinediones (full PPARγ agonists) increase the risk of heart failure despite effective blood glucose reduction in diabetic patients42,43. The gene discussed is PPARG; the disease is heart failure.